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Risk Factors for Nonplatelet Thromboxane Generation After Coronary
Artery Bypass Graft Surgery
Nikolaos Kakouros, MBBS, PhD; Susanna M. Nazarian, MD, PhD; Patrizia B. Stadler, PhD; Thomas S. Kickler, MD; Jeffrey J. Rade, MD
Background-—Persistent thromboxane (TX) generation while receiving aspirin therapy is associated with an increased risk of
cardiovascular events. The Reduction in Graft Occlusion Rates (RIGOR) study found that aspirin-insensitive TXA2 generation,
indicated by elevated urine 11-dehydro-TXB2 (UTXB2) 6 months after coronary artery bypass graft surgery, was a potent risk factor
for vein graft thrombosis and originated predominantly from nonplatelet sources. Our goal was to identify risks factors for
nonplatelet TXA2 generation.
Methods and Results-—Multivariable modeling was performed by using clinical and laboratory variables obtained from 260 RIGOR
subjects with veriﬁed aspirin-mediated inhibition of platelet TXA2 generation. The strongest variable associated with UTXB2
6 months after surgery, accounting for 47.2% of the modeled effect, was urine 8-iso-prostaglandin (PG)F2a, an arachidonic acid
metabolite generated nonenzymatically by oxidative stress (standardized coefﬁcient 0.442, P<0.001). Age, sex, race, lipid therapy,
creatinine, left ventricular ejection fraction, and aspirin dose were also signiﬁcantly associated with UTXB2 (P<0.03), although they
accounted for only 4.8% to 10.2% of the modeled effect. Urine 8-iso-PGF2a correlated with risk of vein graft occlusion (odds ratio
1.67, P=0.001) but was not independent of UTXB2. In vitro studies revealed that endothelial cells generate TXA2 in response to
oxidative stress and direct exposure to 8-iso-PGF2a.
Conclusions-—Oxidative stress–induced formation of 8-iso-PGF2a is strongly associated with nonplatelet thromboxane formation
and early vein graft thrombosis after coronary artery bypass graft surgery. The endothelium is potentially an important source of
oxidative stress–induced thromboxane generation. These ﬁndings suggest therapies that reduce oxidative stress could be useful in
reducing cardiovascular risks associated with aspirin-insensitive thromboxane generation. ( J Am Heart Assoc. 2016;5:e002615
doi: 10.1161/JAHA.115.002615)
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T he cardioprotective property of aspirin derives principallyfrom its antiplatelet effect resulting from the irreversible
inhibition of the cyclooxygenase (COX)-1 enzyme and conse-
quent suppression of platelet thromboxane A2 (TXA2) gener-
ation. In addition to mediating the activation of the platelet in
which it is formed, TXA2 is secreted and directly activates
adjacent quiescent platelets and stimulates vasoconstriction
via binding to surface thromboxane receptors.1 Several
clinical studies have shown that patients with persistent
TXA2 generation while taking aspirin therapy are at increased
risk for atherothrombotic events, including death.2,3
Aspirin therapy is standard of care after coronary artery
bypass graft surgery (CABG) in large part because of its ability
to decrease the rate of vein graft thrombosis by half during
the ﬁrst postoperative year.4 The Reductions in Graft Occlu-
sion Rates (RIGOR) study investigated the hypothesis that
failure of aspirin to adequately inhibit platelet activation would
increase the incidence of early vein graft thrombosis after
ﬁrst-time CABG.5 With the use of arachidonic acid platelet
aggregometry, a speciﬁc indicator of platelet COX-1 activity,
aspirin therapy was found to suppress platelet TXA2 gener-
ation and inhibit aggregation in >95% and >99% of subjects at
3 days and 6 months after surgery, respectively. There was
also no observable association between the rare failure to
suppress platelet TXA2 generation and vein graft occlusion
assessed 6 months after surgery. Despite effective suppres-
sion of platelet-derived TXA2 generation by the use of aspirin,
measurement of urine levels of the stable TXA2 metabolite 11-
dehydroTXB2 (UTXB2) revealed persistent total-body TXA2
generation in 73% and 31% of subjects at 3 days and
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6 months after surgery, respectively. Further, UTXB2
≥450 pg/mg creatinine measured 6 months after CABG
was associated with a 2.6-fold increased risk of vein graft
thrombosis compared with levels of <450 pg/mg creatinine.
These data indicate that a substantial percentage of
patients taking aspirin continue to generate TXA2 6 months
after CABG that originates from predominantly nonplatelet
pathways and is associated with an increased risk of early
vein graft thrombosis. The source and stimuli for nonplatelet
TXA2 generation in patients with cardiovascular disease are
largely unknown. The goal of this study was to use multivari-
able modeling to identify factors associated with nonplatelet
TXA2 generation.
Materials and Methods
Subjects
The Reduction in Graft Occlusion Rates (RIGOR) study was a
multicenter observational study of 368 subjects undergoing
ﬁrst-time CABG between 2003 and 2006 that was designed to
investigate the association between thrombotic risk factors
and early saphenous vein graft occlusion. Patients were
enrolled between October 2003 and October 2006 at 4
participating institutions: Johns Hopkins Hospital, Baltimore,
MD; Christiana Hospital, Christiana, DE; Peninsula Regional
Medical Center, Salisbury, MD; and Walter Reed Army
Hospital, Washington, DC. Institutional human subject
research review board approval was obtained at all partic-
ipating sites, and all subjects provided written consent. A
detailed description of the study design, patient characteris-
tics, and principal ﬁndings has been previously published.5–7
Patients ≥18 years of age undergoing ﬁrst-time CABG with
implantation of at least 1 saphenous vein graft were eligible
for enrollment. Those with an anticipated requirement for
postoperative oral anticoagulation or antiplatelet therapy
other than aspirin were excluded, although those prescribed
these agents for unforeseen postoperative conditions (eg,
atrial ﬁbrillation) continued in the study. All patients were
administered aspirin (300–325 mg) within 24 hours of
surgery. At hospital discharge, patients were given a supply
of 325 mg enteric-coated aspirin and instructed to take 1
tablet daily for 6 months unless directed otherwise by their
physician. Pill counts were performed at each postoperative
encounter. Demographic, historical, procedural, clinical, and
laboratory data were recorded for all patients.
Platelet Studies
Platelet-rich plasma was prepared from blood collected in
3.2% citrate by centrifugation at 100 rpm for 10 minutes, and
the platelet count was adjusted to 180 000/mm3 by the
addition of platelet-poor plasma. Undiluted samples with a
platelet count of <100 000/mm3 were excluded from anal-
ysis. Impedance platelet aggregometry was performed by
stimulation with arachidonic acid (0.5 mmol/L), ADP
(20 lmol/L), epinephrine (50 lmol/L), and collagen (1 lg/
mL) with use of a Chrono-Log Model 560CA aggregometer.
The maximum aggregation response within 5 minutes was
recorded in ohms. Subjects were considered to have aspirin-
induced suppression of signiﬁcant platelet COX-1 activity and
TXA2 generation if arachidonic acid–induced platelet aggre-
gation was absent as indicated by a value of ≤1 Ω (normal
range in our laboratory for aspirin-na€ıve subjects: 5–17 Ω)
based on prior data demonstrating that suppression of
platelet TXA2 generation by >99% is required to suppress
arachidonic acid–induced aggregation by 95%.8 Shear-depen-
dent platelet aggregation was measured by using the Platelet
Function Analyzer-100 (PFA-100) device (Siemens Health-
care Diagnostics) as previously described9 in whole blood
collected in 3.8% citrate. Samples were tested with the
collagen/ADP agonist cartridge, which assesses global
platelet reactivity but is not affected by aspirin. Samples
from subjects with a platelet count <50 000/m3 were
excluded from analysis. Samples with nonclosure were
assigned a closure time (CT) value of 300 seconds, the
maximum measurable by the device.
Measurement of Urine Prostanoids
11-Dehydro-thromboxane B2 (TXB2) was measured in urine
(UTXB2) with ELISA and expressed as a ratio to urine
creatinine as previously described.9 Aspirin responsiveness
based on this assay was deﬁned as UTXB2 <400 pg/mg
creatinine according to established criteria.10
Assessment of Saphenous Vein Graft Patency
Vein graft patency was assessed 6 months after CABG by the
use of multidetector computed tomography coronary–angiog-
raphy as previously described.6 Data from clinically driven
invasive coronary angiograms could be used for the primary
end point analysis if performed within 6 weeks of the
anticipated 6-month follow-up visit or if it was the only
assessment of vein graft patency before an adverse clinical
end point. Multisegmented grafts were statistically consid-
ered as separate vein grafts according to the Society of
Thoracic Surgeons criteria. Reconstructed images were
analyzed by 2 blinded reviewers and classiﬁed as patent
(containing stenoses of 0–75%), signiﬁcantly diseased (con-
taining stenoses of 76–99%), or occluded (containing a 100%
stenosis). There was 98% concordance in assessment of vein
graft patency between reviewers. In cases of discordance, a
third reviewer adjudicated all vein grafts in that patient.
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In Vitro Prostanoid Generation
Human umbilical vein endothelial cells weremaintained in EGM-
2 medium (Lonza) at 37°C under 5% CO2. Conﬂuent cells in
10-cm plates were stimulated with hydrogen peroxide (Sigma-
Aldrich) and 8-iso-prostaglandin (PG)F2a (Cayman Chemical) for
1 hour at the indicated concentrations. Conditioned media
were spiked with tetradeuterated 11-dehydro-TXB2, TXB2, and
8-iso-PGF2a (Cayman Chemical) as internal standards before
solid phase extraction by using 50-mg BondElut C18 reverse
phase cartridges (Agilent Technologies) preconditioned with
ethanol and water to concentrate eicosanoid species. Acidiﬁed
samples (2% formic acid) were loaded and washed sequentially
with water, 15% ethanol, and hexane and then eluted with ethyl
acetate, dried, and resuspended in 15% acetonitrile. Calibrants
were prepared in the same way over a 0.5- to 500-ng/mL
concentration range. Liquid chromatography/mass spectrom-
etry (MS)–MS was performed by using a Dionex UltiMate 3000
UHPLC system in line with a TSQ Quantiva triple quadruple
mass spectrometer (Thermo Fisher Scientiﬁc). Chromato-
graphic separation was performed with a Kinetex C18
(1.7 lm, 100 A) 509100-mm column maintained at 40°C. A
multistep gradient with (A) water with 0.005% (v/v) acetic acid,
pH 5.7, and (B) 5% methanol/95% acetonitrile with 0.005%
acetic acid, at a ﬂow rate of 0.6 mL/min was used. After a 15-
lL injection, the gradient started at 15% B (0–0.6 minutes),
increased to 40% B (0.6–2 minutes), increased to 95% B (2–
4 minutes), was maintained at 95% B (4–4.5 minutes),
decreased to 15% B (4.5–4.7 minutes), and was maintained
at 15% B (4.7–8 minutes). Tandem MS was performed in
negative ion mode with spray voltage set at 3.3 kV, ion transfer
tube temperature at 356°C, and vaporizer temperature at
420°C. The sheath, auxillary, and sweep gases were set at 52,
16, and 2 AU, respectively. The following m/z transitions were
monitored for quantiﬁcation: m/z 353.2?193.1 (CE 26 eV)
and 353.2?309.1 (CE 20 eV) for 8-iso-PGF2a; 357.2?197.1
(CE 26 eV) and 357.2?313.1 (CE 20 eV) for d4-iso-PGF2a,m/
z 367.2?243.1 (CE 20 eV) and 367.2?305.1 (CE 16 eV) for
11-dehydro-TXB2; m/z 371.2?247.1 (CE 20 eV) and 371.2?
309.1 (CE 16 eV) for d4-11-dehydro-TXB2; 369.2?169.1 (CE
18 eV) and 369.2?195.0 (CE 15 eV) for TXB2; and 373.2?
173.1 (CE 18 eV) and 373.2?199.0 (CE 15 eV) for d4-TXB2.
Area ratios of analyte to internal standard were calculated, and
concentrations of the samples were determined from the
standard curve. All data were processed and integrated in
Xcalibur, version 3.0 (Thermo).
Statistical Analysis
UTXB2 values were normalized by using the natural logarith-
mic transform. Univariate analyses were performed by using
those variables deemed biologically plausible or supported by
the literature. Colinearity of covariates was tested by using
Fisher exact and Pearson correlation for categorical and
continuous variables, eliminating highly collinear covariates
based on clinical signiﬁcance. All predictors with P≤0.15 on
univariate analysis were included in a multivariable model that
was optimized by using the corrected Akaike Information
Criterion. To facilitate comparison of the contribution of
independent variables in the multivariable model, the coefﬁ-
cient estimates are reported for independent variables
standardized to a variance of 1 (b coefﬁcients). The relative
importance of the independent variables was further assessed
by dominance analysis.11 The regression was performed for
all possible combinations of the identiﬁed predictors, the
incremental contribution of each variable to the resulting
models was averaged to obtain general dominance (additive
decomposition), and conditional dominance evaluations were
performed. The independent variables were ranked for their
contribution to the multivariable model based on their
dominance weights. For vein graft analysis, grafts classiﬁed
as severely diseased were considered as patent. Univariate
analyses were performed on a per-graft basis for the odds of
occlusion versus patency for UTXB2 and urinary (U)8-iso-
PGF2a. Proportions were compared by using a v
2 or Fisher’s
exact test, and comparisons among groups were made with
ANOVA, McNemar, or Kruskal–Wallis testing, as appropriate.
Analyses were performed by using Stata/MP 10.0 for
Windows (StatCorp). Differences were considered signiﬁcant
when P<0.05.
Results
Study Population Characteristics
Of the 368 subjects undergoing ﬁrst-time CABG enrolled in
the RIGOR study, 299 had measurement of UTXB2 and
platelet reactivity at the time of assessment of vein graft
patency 6 months after surgery. Thirty-nine subjects were
excluded from the primary analyses: 2 because they had
discontinued aspirin, 32 because they were taking additional
nonaspirin antiplatelet agents, and 5 because of arachidonic
acid–induced platelet aggregation ≥1 Ω despite aspirin
therapy. Therefore, 260 subjects taking aspirin monotherapy
with veriﬁed suppression of platelet COX-1 activity and TXA2
generation by >99%8 were used for the primary analyses.
UTXB2 in this study cohort was non–normally distributed
(Figure 1) with a median of 328 pg/mg creatinine (IQR 232–
451 pg/mg creatinine). Despite conﬁrmed aspirin-induced
suppression of arachidonic acid–induced platelet activation,
82 (31.5%) subjects had UTXB2 ≥400 pg/mg creatinine, the
accepted threshold with this assay for deﬁning putative
aspirin nonresponsiveness.10 Table 1 shows the clinical
characteristics of the study cohort as a whole, in subjects
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stratiﬁed by UTXB2, and in subjects excluded from the primary
analyses.
Relationship Between Clinical and Laboratory
Variables and UTXB2
To identify potential stimuli and sources for nonplatelet
thromboxane generation, univariate analyses were used to
explore associations of a wide array of demographic, clinical,
and laboratory variables to UTXB2 expressed as a continuous
variable (Tables 2 and 3). A multivariable model (ﬁt statistic of
0.44, P<0.0001) was then constructed to identify indepen-
dent predictors of UTXB2 (Table 4). The strongest predictor of
UTXB2, accounting for nearly half of the modeled effect, was
U8-iso-PGF2a, an isoprostane formed by nonenzymatic
metabolism of arachidonic acid under conditions of oxidative
stress.12 Figure 2 shows the high degree of correlation
between normalized values of U8-iso-PGF2a and UTXB2 in the
study population. Age, race, and sex were also independently
associated with UTXB2 and accounted for 10% of the
modeled effect, while lipid therapy (predominantly statins),
renal function, left ventricular function, and aspirin dose
contributed to lesser degrees.
Relationship of U8-Iso-PGF2a to Early Vein Graft
Failure
We previously found that aspirin-insensitive thromboxane
generation, deﬁned by elevated UTXB2, was a novel and
independent risk factor for vein graft thrombosis 6 months
after CABG.5 Given that U8-iso-PGF2a is a major determinant
of UTXB2, we investigated whether there was a direct
relationship of the former to early graft thrombosis. Stratiﬁ-
cation of RIGOR subjects, regardless of antiplatelet use or
aspirin responsiveness, by tertile of U8-iso-PGF2a, revealed a
proportional increase in the prevalence of vein graft occlusion
(Figure 3), and normalized U8-iso-PGF2a correlated with graft
occlusion when considered on a per-graft basis (odds ratio
1.67, P=0.001). U8-iso-PGF2a was not, however, an indepen-
dent predictor of vein graft occlusion in multivariable mod-
eling when UTXB2 was included as a variable (data not
shown), indicating the primacy of the latter.
Relationship Between Endothelial Thromboxane
Generation and Oxidative Stress
The strong association between U8-iso-PGF2a and UTXB2
highly suggests, but does not in itself prove, a causal
relationship between oxidative stress and nonplatelet TXA2
generation. Because the endothelium is a potential major
source of nonplatelet TXA2 generation in vivo, we determined
the effect of oxidative stress and direct stimulation with 8-iso-
PGF2a on endothelial TXA2 generation. Exposure of human
umbilical vein endothelial cells to hydrogen peroxide resulted
in a dose-dependent increase in the concentration of 8-iso-
PGF2a, TXB2, and 11-dehydro-TXB2 in the conditioned media,
indicative of cellular TXA2 generation (Figure 4A). Further,
direct stimulation of human umbilical vein endothelial cells
with 8-iso-PGF2a results in endothelial TXA2 production
(Figure 4B), establishing a mechanistic link among oxidative
stress, 8-iso-PGF2a formation, and nonplatelet TXA2
generation.
Discussion
The major ﬁndings of this study are that (1) oxidative stress–
induced formation of 8-iso-PGF2a is the strongest variable
associated with nonplatelet TXA2 generation in patients
6 months after CABG; (2) age, sex, race, lipid therapy, aspirin
dose, and kidney and left ventricular function are also
independently associated with nonplatelet TXA2 generation,
though to a much lesser degree; (3) U8-iso-PGF2a directly
correlates with incidence of early vein graft thrombosis, but
its predictive power is not independent of UTXB2; and (4)
endothelial cells are capable of generating TXA2 in response
to both oxidative stress and direct stimulation with 8-iso-
PGF2a, thus representing a potential source of nonplatelet
TXA2 generation in vivo.
Platelets are the predominant source of TXA2 generation in
healthy individuals, and measurement of stable TXA2 metabo-
lites in the urine has been used clinically as an indicator of the
antiplatelet effects of aspirin. Substudies from the Heart
Outcomes Prevention Evaluation (HOPE) and the Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization,
Management and Avoidance (CHARISMA) trials found that in
Figure 1. Distribution of urine 11-dehydroTXB2 (UTXB2) in the
study cohort of 260 subjects. The blue dashed line indicates the
putative threshold for deﬁning aspirin responsiveness with this
assay.10
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patients with either established or at high risk for cardiovas-
cular disease who are receiving aspirin therapy, those with
UTXB2 in the highest quartile had a 1.66- to 1.80-fold
increased risk of death, myocardial infarction, and stroke
compared those in the lowest quartile.2,3 An early interpre-
tation of these results was that aspirin failed to adequately
inhibit platelet COX-1 activity in a substantial number of
subjects, leading to persistent TXA2 generation, increased
Table 1. Baseline, Operative, and Postoperative Characteristics of the 260 Study Subjects Stratiﬁed by UTXB2 and the 39
Excluded Subjects
Characteristic <400 pg/mg Creatinine ≥400 pg/mg Creatinine P Value Total Included Total Excluded P Value
No. of patients 178 82 260 39
Age, y 63 (55–69) 66 (57–73) 0.07 63 (56–71) 63 (59–72) 0.44
Male sex 153 (86%) 58 (71%) 0.006 211 (81%) 25 (64%) 0.02
White race 17 (10%) 18 (22%) 0.01 35 (13%) 5 (13%) 1.0
Body mass index, kg/m2 29 (26–33) 28 (26–33) 0.87 29 (26–33) 26 (24–30) <0.001
Medical history, n
Hypertension 148 (83%) 65 (79%) 0.49 213 (82%) 32 (84%) 0.82
Dyslipidemia 150 (85%) 65 (79%) 0.29 215 (83%) 34 (89%) 0.48
Diabetes 56 (32%) 39 (48%) 0.018 95 (37%) 11 (29%) 0.47
Heart failure 16 (9%) 18 (22%) 0.006 34 (13%) 4 (10%) 0.80
Peripheral/cerebrovascular disease 28 (16%) 18 (22%) 0.226 46 (18%) 8 (21%) 0.66
Atrial fibrillation 5 (3%) 3 (4%) 0.71 8 (3%) 4 (10%) 0.06
Current tobacco use 33 (19%) 27 (33%) 0.017 60 (23%) 11 (28%) 0.55
Myocardial infarction 64 (36%) 39 (48%) 0.08 103 (40%) 18 (46%) 0.49
Prior PCI 40 (22%) 12 (15%) 0.18 52 (20%) 9 (23%) 0.67
Preoperative LVEF 0.78 0.75
≤30% 14 (8%) 8 (10%) 22 (8%) 3 (8%)
30–50% 59 (33%) 29 (35%) 88 (34%) 11 (28%)
>50% 105 (59%) 45 (55%) 150 (58%) 25 (64%)
Urgent/emergent surgery 100 (56%) 57 (70%) 0.06 157 (60%) 30 (77%) 0.052
Euroscore 3 (1–5) 4 (3–6) 0.004 3 (2–5) 4 (2–5) 0.25
Arterial graft implanted 175 (98%) 79 (96%) 0.38 254 (98%) 36 (92%) 0.10
No. of SVGs per subject 0.2 0.03
1 48 (27%) 20 (24%) 68 (26%) 17 (44%)
2 70 (39%) 41 (50%) 111 (43%) 12 (31%)
3 44 (25%) 12 (15%) 56 (22%) 10 (26%)
≥4 16 (9%) 9 (11%) 25 (10%) 0 (0%)
Medications at the time of SVG patency assessment
Aspirin 178 (100%) 82 (100%) 1.0 260 (100%) 37 (95%) <0.001
Nonaspirin antiplatelet 0 (0%) 0 (0%) 1.0 0 (0%) 33 (85%) <0.001
Aspirin low dose (<325 mg) 11 (6%) 10 (12%) 0.14 21 (8%) 12 (31%) <0.001
Oral anticoagulation 6 (3%) 7 (9%) 0.12 13 (5%) 3 (8%) 0.49
b-Blocker 153 (86%) 61 (75%) 0.035 214 (82%) 35 (90%) 0.36
ACE inhibitor/ARB 113 (63%) 47 (57%) 0.4 160 (62%) 26 (67%) 0.60
Lipid-lowering agent 162 (91%) 65 (79%) 0.015 227 (87%) 37 (95%) 0.28
Values are median (IQR) or n (%). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; SVG, saphenous vein graft; UTXB2, urinary thromboxane B2.
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platelet reactivity, and elevated cardiovascular risk. The
RIGOR study also found that elevated UTXB2 was associated
with increased cardiovascular risk, being a potent and
independent risk factor for early vein graft thrombosis.5
Unlike the HOPE and CHARISMA data, which did not measure
Table 2. Univariate Analyses of the Associations of Subject
Demographics, Past Medical History and Medication Use With
UTXB2 (Normalized by Natural Log Transformation of pg/mg
Creatinine)
Characteristic
Standardized
Coefﬁcient* P Value
Female sex 0.225 <0.001
Age, y 0.203 0.001
White race (versus nonwhite) 0.188 0.006
Obesity (BMI ≥30 kg/m2) 0.101 0.093
Medical history
Hypertension 0.031 0.579
Dyslipidemia 0.141 0.030
Diabetes 0.110 0.091
Current tobacco use 0.155 0.011
Former tobacco use 0.097 0.111
Myocardial infarction 0.052 0.394
Percutaneous coronary intervention 0.054 0.272
Congestive heart failure 0.140 0.015
Cerebrovascular disease 0.044 0.524
Deep venous thrombosis/pulmonary
embolus
0.027 0.436
Peripheral vascular disease 0.167 0.010
Chronic obstructive pulmonary disease 0.139 0.016
Atrial fibrillation 0.038 0.581
Preoperative LVEF: <30% vs 30–50% 0.110 0.360
Preoperative LVEF: <30% vs ≥50% 0.148 0.211
Left ventricular ejection fraction (%) 0.157 0.011
Euroscore: 0–2 vs 3–5 0.227 0.001
Euroscore: 0–2 vs ≥6 0.281 <0.001
CABG urgency: elective vs urgent or emergent 0.044 0.501
Medications
Aspirin dose (81 mg vs higher) 0.187 0.003
Oral anticoagulation 0.124 0.088
b-Blocker 0.096 0.112
Angiotensin II receptor blocker 0.046 0.488
Angiotensin-converting enzyme inhibitor 0.029 0.636
Lipid therapy 0.195 0.001
Diuretic 0.046 0.457
Insulin 0.020 0.726
Insulin sensitizer 0.004 0.954
Insulin secretagogue 0.064 0.346
BMI indicates body mass index; CABG, coronary artery bypass graft surgery; LVEF, left
ventricular ejection fraction; UTXB2, urinary thromboxane B2.
*Coefﬁcients are standardized to 1 SD of the predictor. Huber–White sandwich
estimates were used to produce robust estimates of variance.
Table 3. Univariate Analyses of the Associations of
Laboratory Variables to UTXB2 (Normalized by Natural Log
Transformation of pg/mg Creatinine)
Characteristic
Standardized
Coefﬁcient* P Value
Hematologic parameter
Leukocyte count: 4.5–119103 mm3 Reference
Leukocyte count: ≤4.59103 mm3 0.023 0.702
Leukocyte count: ≥119103 mm3 0.078 <0.001
MCV 80–100 fL Reference
MCV <80 fL 0.067 0.354
MCV >100 fL 0.003 0.925
Hematocrit (%) 0.089 0.183
Red cell distribution width (≤14.5 vs
>14.5%)
0.130 0.042
RDW, %3 0.141 0.024
Platelet count (<150 vs
≥1509103 mm3)
0.032 0.582
Reticulocyte (ln %) 0.083 0.273
Mean platelet volume (%1) 0.050 0.401
Immature platelet fraction (ln %) 0.055 0.390
Blood group: O vs other 0.015 0.805
Rh positivity 0.071 0.341
Creatinine ([mg/dL]½) 0.166 0.002
C-reactive protein (<5 vs ≥5 mg/L) 0.139 0.027
Fibrinogen <390 vs ≥390 mg/dL 0.124 0.049
vonWillebrand factor (>150% vs ≤150%) 0.192 0.002
Urine 8-iso-PGF2a (ln pg/mg creatinine) 0.500 <0.0001
Urine 8-iso-PGF2a (<1061 vs ≥1061 pg/mg
creatinine)
0.353 <0.001
Fasting serum insulin (ln lU/mL) 0.008 0.91
Impedance platelet aggregation in ohms to
ADP (20 lmol/L) 0.041 0.452
Collagen (1 lg/mL) 0.006 0.910
Epinephrine (50 lmol/L) 0.078 0.188
PFA-100 collagen/ADP (closure time in s) 0.014 0.811
PFA-100 collagen-epinephrine (closure
time in s)
0.097 0.147
MCV indicates ; PG, prostaglandin; RDW, ; UTXB2, urinary thromboxane B2..
*Coefﬁcients are standardized to 1 SD of the predictor. Huber–White sandwich
estimates were used to produce robust estimates of variance.
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platelet-speciﬁc TXA2 generation, the RIGOR data revealed
that failure of aspirin to inhibit platelet COX-1 and TXA2
generation was in fact rare, occurring in <1% of subjects
6 months after surgery. This provided compelling evidence
that aspirin-insensitive TXA2 generation in patients with
cardiovascular disease, unlike in healthy individuals, predom-
inantly originates from nonplatelet sources.
The current analysis extends our previous results and
identiﬁes oxidative stress as a potentially major stimulus for
nonplatelet TXA2 generation by showing a strong correlation
with 8-iso-PGF2a, an arachidonic acid metabolite formed
nonenzymatically in a variety of cell types by free radical
oxidation.12 While frequently used as a marker of oxidative
stress, 8-iso-PGF2a is also a biologically active prostanoid that
can bind to and activate cellular thromboxane receptors (see
reviews13 and 14). Although it is not as potent a platelet
agonist as TXA2, 8-iso-PGF2a can potentiate platelet activation
in response to collagen and ADP as well as directly stimulate
vasoconstriction. In 2 small prior studies involving patients
with unstable angina and diabetes who were taking aspirin, a
correlation between UTXB2 and 8-iso-PGF2a was identiﬁed,
though in neither was the source of TXA2 generation
speciﬁcally evaluated.15,16 Our analysis not only establishes
a strong association between 8-iso-PGF2a and aspirin-
insensitive TXA2 generation in a larger study cohort but also
conclusively demonstrates that the latter originates predom-
inantly from nonplatelet sources.
Mounting evidence suggests that oxidative stress―
induced generation of 8-iso-PGF2a and nonplatelet TXA2 is
more than just linearly associated but is causally linked.
Treatment with the antioxidant vitamin E has been shown to
reduce both U8-iso-PGF2a and UTXB2 levels in aspirin-na€ıve
smokers.17 More deﬁnitive are the ﬁndings that fetal porcine
cerebral and retinal microvessels generate TXA2 when
incubated with 8-iso-PGF2a, an effect that is blocked by
indomethacin.18,19 Our data not only conﬁrm this ﬁnding in
macrovascular endothelial cells but also reveal that oxidative
stress itself can be a primary stimulus for endothelial TXA2
generation. Whether this effect is mediated by the endothelial
Table 4. Independent Risk Factors for UTXB2* After Adjustment of Other Variables by Multivariable Regression Analysis
Characteristic Standardized Coefﬁcient P Value Dominance Weight Dominance Ranking
Urine 8-iso-PGF2a (ln pg/mg creatinine) 0.442 <0.001 0.472 1
Age, y 0.239 <0.001 0.102 2
Female sex 0.129 0.015 0.093 3
White race (versus nonwhite) 0.172 0.009 0.085 4
Lipid therapy 0.161 0.004 0.077 5
Creatinine ([mg/dL]½) 0.152 0.002 0.072 6
Aspirin dose (81 mg vs higher) 0.145 0.004 0.052 7
Left ventricular ejection fraction (%) 0.113 0.032 0.048 8
PG indicates prostaglandin; UTXB2, urinary 11-dehydro thromboxane B2 (pg/mg creatinine).
*Normalized using natural log transform.
Figure 3. Prevalence of saphenous vein graft
(SVG) occlusion in 225 subjects stratiﬁed by tertile
of urine 8-iso-prostaglandin (PG)F2a.
Figure 2. Linear regression of normalized levels of urine 11-
dehydro-thromboxane (TX)B2 to 8-iso-prostglandin (PG)F2a in 228
subjects.
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generation of 8-so-PGF2a and autocrine stimulation of cellular
thromboxane receptors or involves additional intracellular
pathways is an area of active investigation.
Because 8-iso-PGF2a is a stable prostanoid that freely
circulates, its biological effects can be widespread and
distinct from sources of origin. Inﬂammatory cells are capable
of directly generating TXA2 and 8-iso-PGF2a, and patients
undergoing cardiac surgery with cardiopulmonary bypass have
a marked inﬂammatory response with an observable increase
in U8-iso-PGF2a in the early postoperative period.
20–22 In the
RIGOR study, UTXB2 was signiﬁcantly higher 3 days after
CABG than at 6 months, though only the latter correlated with
risk of vein graft occlusion.5 While we did ﬁnd signiﬁcant
correlations of UTXB2 with white blood cell count, C-reactive
protein, or ﬁbrinogen on univariate analyses, none of these
variables was independently associated with UTXB2, suggest-
ing that inﬂammation was not a major stimulus for nonplatelet
TXA2 generation 6 months after CABG. It is conceivable that
the vein grafts themselves contribute to TXA2 generation
given that surgical preparation and pressure-induced disten-
tion are known to increase oxidative stress in vein seg-
ments.23,24 However, we did not observe any correlation
between the number of vein graft segments implanted at the
time of surgery and either UTXB2 or U8-iso-PGF2a 6 months
later (data not shown). The elevated UTXB2 and U8-iso-PGF2a
observed in a substantial percentage of the RIGOR study
cohort are, therefore, likely due predominantly to underlying
cardiovascular disease or its risk factors, rather than effects
of the CABG per se. UTXB2 has previously been shown to be
elevated in diabetics compared with nondiabetics.16 While
this was also true in our analysis, diabetes was not found to
be an independent predictor of UTXB2 when 8-iso-PGF2a was
considered as a variable, suggesting that they are different
manifestations of the same pathologic process.
The mechanism by which nonplatelet TXA2 generation
could adversely affect cardiovascular risk is currently
unknown. TXA2 necessarily acts locally because of a short
half-life (30 seconds) due to degradation to biologically inert
TXB2. Although aspirin-inhibited platelets cannot generate
appreciable amounts of TXA2, they could potentially still
aggregate in response to locally generated nonplatelet TXA2
to cause thrombosis. However, several pieces of evidence
argue against platelet hyperreactivity being a major mediator
of cardiovascular risk by nonplatelet TXA2 generation. First,
the addition of clopidogrel did not reduce cardiovascular risk
in CHARISMA subjects with elevated UTXB2.
3 Second, UTXB2
in the RIGOR study cohort was independent of multiple
parameters of platelet reactivity, including shear-dependent
platelet aggregation and whole blood aggregation performed
in response to multiple different agonists (Table 3). Third, we
found no correlation between U8-iso-PGF2a and platelet
reactivity, suggesting that circulating 8-iso-PGF2a did not
signiﬁcantly “prime” or potentiate platelet aggregation in
response to more physiologic agonists (data not shown).
Rather than potentiating platelet reactivity, local TXA2 gener-
ation could predispose to thrombus formation by altering
endothelial thromboresistance. Consistent with this concept
are the recent ﬁndings that thromboxane receptor activation
stimulates tissue factor expression in both endothelial cells
and monocytes.25,26
A signiﬁcant ﬁnding of our analysis was that U8-iso-PGF2a
correlated directly with the incidence of early vein graft
thrombosis. This suggests that therapies aimed at reducing
oxidative stress might be a viable strategy to reduce
nonplatelet TXA2 generation and improve outcomes after
cardiac surgery. Antioxidants have been shown to be
efﬁcacious at reducing the incidence of postoperative atrial
ﬁbrillation.27,28 While they have not been evaluated for
Figure 4. A, Human umbilical vein endothelial cells (HUVECs) under oxidative stress by exposure to hydrogen peroxide (H2O2) for 1 hour
generate thromboxane (TX) and isoprostanes in a dose-dependent manner. B, HUVECs exposed to 8-iso-prostaglandin (PG)F2a for 1 hour
generate thromboxane in a dose-dependent manner. Values shown are the mean of n=3 SEM.
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efﬁcacy at reducing graft failure, this is an eminently testable
hypothesis.
Our study has several potential limitations. Although we
examined a wide array of clinical and laboratory variables
associated with UTXB2 generation in subjects 6 months after
CABG, presumably at a time when the effects of surgery have
subsided, it is possible that the relative contributions of
oxidative stress and other identiﬁed factors differ in popula-
tions with various forms or severity of cardiovascular disease.
Although the RIGOR cohort was extensively phenotyped and
we evaluated numerous potential variables, the 8 variables
identiﬁed in the multivariable modeling account for only
slightly less than half of the modeled effect on UTXB2. Thus,
additional risk factors for nonplatelet TXA2 generation remain
to be identiﬁed.
In summary, we identiﬁed several risk factors for non-
platelet TXA2 generation in subjects 6 months after CABG.
Not only was oxidative stress-induced formation of 8-iso-
PGF2a the strongest identiﬁed risk factor, but it also directly
correlated with risk of early vein graft thrombosis. In vitro
studies revealed that macrovascular endothelial cells are
capable of generating TXA2 under conditions of oxidative
stress and with direct stimulation with 8-iso-PGF2a, not only
establishing a mechanistic link between oxidative stress and
nonplatelet TXA2 generation but pointing to dysfunctional
endothelial cells as a potentially major source. These ﬁndings
provide valuable insights into the pathobiology of nonplatelet
TXA2 generation and identify potential therapeutic strategies
for its suppression.
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